Literature DB >> 15219643

Growth hormone response to clonidine predicts aggression in Alzheimer's disease.

Nathan Herrmann1, Krista L Lanctôt, Goran Eryavec, Robert Van Reekum, Lyla R Khan.   

Abstract

OBJECTIVE: The neurobiology of aggression in Alzheimer's Disease (AD) remains unknown. The objective of this study was to determine if altered central noradrenergic (NE) responsiveness is related to aggression in AD.
METHODS: Fifteen institutionalized, non-depressed elderly (11 males, four females, mean age 81.5 +/- 5.5) with probable AD, severe cognitive impairment (MMSE mean 3.3 +/- 4.6) and significant behavioral disturbances (Neuropsychiatric Inventory (NPI) score > or = 8) were studied. Growth Hormone (GH) response to clonidine challenge (5 microg/kg) was used as an index of central alpha(2)-adrenergic function.
RESULTS: When patients were divided into those with preserved GH response (GH maximum change from baseline > 0, n = 6) and those with blunted GH response (GH maximum change from baseline < or = 0, n = 9) there were significant differences in levels of aggression as measured by the Cohen-Mansfield Agitation Inventory (CAMI) physical aggression subscale (p = .026). Patients with blunted GH response also had significantly higher levels of aggression against others on the retrospective Overt Aggression Scale (p = 0.027).
CONCLUSIONS: Certain types of physically aggressive behaviors are associated with a blunted GH response to clonidine challenge. This finding is consistent with compensatory down-regulation of post-synaptic alpha(2)-adrenergic receptors in response to enhanced NE outflow in aggressive AD patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219643     DOI: 10.1016/j.psyneuen.2004.02.001

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  5 in total

Review 1.  Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management.

Authors:  Dag Aarsland; Sally Sharp; Clive Ballard
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 2.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

3.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

Review 4.  Behavioral and psychological symptoms in Alzheimer's disease.

Authors:  Xiao-Ling Li; Nan Hu; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

Review 5.  Pharmacological interventions for apathy in Alzheimer's disease.

Authors:  Myuri T Ruthirakuhan; Nathan Herrmann; Eleenor H Abraham; Sarah Chan; Krista L Lanctôt
Journal:  Cochrane Database Syst Rev       Date:  2018-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.